BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
Abstract PARP inhibitors have been approved for the therapy of cancers with homologous recombination (HR) deficiency based on the concept of “synthetic lethality”. However, glioblastoma (GBM) patients have gained little benefit from PARP inhibitors due to a lack of BRCA mutations. Herein, we demonst...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-05-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-021-03805-6 |